Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) today. The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, ...

On Monday, BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $8.19 which represents a slight increase of $0.41 or 5.27% from the prior close of $7.78. The stock opened ...

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...

JP Morgan has recently resumed BioCryst Pharmaceuticals Inc (BCRX) stock to Overweight rating, as announced on November 20, 2023, according to Finviz. Earlier, on September 18, 2023, RBC Capital Mkts ...

A Durham company says its drug is pacing for over $400 million in revenue this year. The goal is $1 billion.

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of $10.00. The ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Good day and Welcome to the BioCryst Third Quarter 2024 Earnings ...

BioCryst Pharmaceuticals Inc (BCRX) reports robust revenue growth and strategic progress, while navigating market challenges and future opportunities.

BioCryst Pharmaceuticals (NASDAQ: BCRX) Q3 2024 Earnings Call Nov 04, 2024, 8:30 a.m. ET Good day and Welcome to the BioCryst ...

The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million. BioCryst expects full-year revenue in the range of ...